Exhibit 460

Report 54: Infants and Children Under 12 Given the Pfizer mRNA COVID "Vaccine" Seven Months BEFORE Pediatric Approval. 71% of Adverse Event Cases Classified as Serious

https://dailyclout.io/report-54-infants-and-children-under-12-given-the-pfizer-mrna-covid-vaccine-seven-months-before-pediatric-approval-71-suffered-serious-adverse-events/

Report 54: Infants and Children Under 12 Given the Pfizer mRNA COVID "Vaccine" Seven Months BEFORE Pediatric Approval. 71% of Adverse Event Cases Classified as Serious.

January 31, 2023 • by Barbara Gehrett, MD; Joseph Gehrett, MD; Chris Flowers, MD; and Loree Britt

The War Room/DailyClout Pfizer Documents Analysis Project Post-Marketing Group (Team 1) – Barbara Gehrett, MD; Joseph Gehrett, MD; Chris Flowers, MD; and Loree Britt – produced a shocking review of the pediatric data found in Pfizer document *5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-FEB-2021* (https://www.phmpt.org/wp-content/uploads/2022/04/reissue_5.3.6-postmarketing-experience.pdf) (a.k.a., "*5.3.6*").

It is important to note 1) that the adverse events (AEs) in the *5.3.6* document were reported to Pfizer for only a 90-day period starting on December 1, 2020, the date of the United Kingdom's public rollout of Pfizer's COVID-19 experimental mRNA "vaccine" product and 2) **no pediatric dose of the Pfizer product was approved for use during that time frame**.

What dose(s) of Pfizer's mRNA "vaccine" was given to these children since no approved dose existed?

Important points from this report include:

- **A seven-year-old experienced a stroke**.
- **One child and one infant suffered facial paralysis**.
- **One infant had a kidney adverse event, either kidney injury or failure**.
- Of the 34 adverse event cases, **24 (71%) were classified as serious**.
- **Predominantly female patients were affected —** at least 25 of 34 (73.5%) patients.
- Table 6 reports **34 cases of use in pediatric individuals**. However, **28 additional cases were excluded** because details such as height and weight were "not consistent with pediatric subjects."
- Ages ranged from **two months to nine years**, with **median 4.0 years**, which means **half the children were under four years of age**.
- 132 adverse events were reported in the 34 children – i.e., **an average of 3.88 AEs per child**.

Shockingly, Pfizer concluded:

"***No new significant safety information was identified based on a review of these cases compared with the non-paediatric population***."

Please read the disturbing, two-page report by the Post-Marketing Group (Team 1) below.

DAILYCLOUT

War Room/DailyClout Pfizer Document Analysis

Post-Marketing Team Micro-Report 6:

Review of 5.3.6 - Use in Pediatric Individuals < 12 years of age

SOURCE:
https://www.phmpt.org/wp-content/uploads/2022/04/reissue_5.3.6-postmarketing-experience.pdf

5.3.6 AE REPORTING PERIOD:

"Since the first temporary authorization for emergency supply under Regulation 174 in the UK (01 December 2020) and through 28 February 2021."

ABBREVIATIONS:

5.3.6 : Pfizer source document

SOC : System Organ Class

AE : Adverse Event

AESI : Adverse Event of Special Interest

EUA : Emergency Use Authorization by FDA

PM : Post-Marketing

BNT162b2 : Pfizer's mRNA COVID-19 vaccine

SEQUELAE: an abnormal condition resulting from a previous disease, injury, or other trauma

AGE GROUPS defined in 5.3.6 (p. 25 footnote) :

Adult	18 - 64
Elderly	≥ 65
Child	2 - 11
Adolescent	12 - < 18
Infant	1 – 23 months

AUTHORS:

Dr Barbara Gehrett MD
Dr Joseph Gehrett MD
Dr Chris Flowers MD
Loree Britt

Post Marketing Team

28Jan23

Infants and children under 12 were injected with the Pfizer "vaccine" seven months before the product was approved for children.

The 5.3.6 document was compiled by Pfizer for the purpose of reporting adverse events to the FDA. The reporting period was during the first 90 days, starting December 1, 2020, after the COVID-19 "vaccine" rollout to the public. This experimental product was not approved for use in the < 12 years of age group at that time.

Who was responsible for administering this unapproved product to children? Did these children receive a full or a partial adult dose? Who decided how much to inject? Were the AEs in these children monitored long term? Were the results of final outcomes of this inappropriate administration utilized when the approval for this age group was considered? These questions are not answered in the 5.3.6 document.

In Pfizer's 5.3.6 document, Tables 3, 4, 5 and 6 present a summary of information the FDA requested from the Pfizer Pharmacovigilance Plan: *"Please include a cumulative analysis of the Important Identified Risks, Important Potential Risks, and Areas of Important Missing Information identified in your Pharmacovigilance Plan, …"*

In response, Pfizer identified three categories of Safety Concerns in Table 3:

Table 3. Safety concerns

Important identified risks	Anaphylaxis
Important potential risks	Vaccine-Associated Enhanced Disease (VAED), Including Vaccine-associated Enhanced Respiratory Disease (VAERD)
Missing information	Use in Pregnancy and lactation Use in Paediatric Individuals <12 Years of Age Vaccine Effectiveness

https://www.phmpt.org/wp-content/uploads/2022/04/reissue_5.3.6-postmarketing-experience.pdf

Table 6. Description of Missing Information

Topic	Description
Missing Information	Post Authorization Cases Evaluation (cumulative to 28 Feb 2021) Total Number of Cases in the Reporting Period (N=42086)
	• In 4 cases (3 non-serious; 1 serious) Suppressed lactation occurred in a breast feeding women with the following co-reported events: Pyrexia (2), Paresis, Headache, Chills, Vomiting, Pain in extremity, Arthralgia, Breast pain, Scar pain, Nausea, Migraine, Myalgia, Fatigue and Breast milk discolouration (1 each). Conclusion: There were no safety signals that emerged from the review of these cases of use in pregnancy and while breast feeding.
Use in Paediatric Individuals <17 Years of Age	Paediatric individuals <12 years of age • Number of cases: 34* (0.1% of the total PM dataset), indicative of administration in paediatric subjects <12 years of age; • Country of incidence: UK (29), US (3), Germany and Andorra (1 each); • Cases Seriousness: Serious (24), Non Serious (10); • Gender: Females (23), Males (7), Unknown (2), • Age (n=34) ranged from 2 months to 9 years, mean = 3.7 years, median = 4.0; • Case outcome: resolved/resolving (16), not resolved (13), and unknown (5). • Of the 132 reported events, those reported more than once were as follows: Product administered to patient of inappropriate age (27, see Medication Error), Off label use (11), Pyrexia (6), Product use issue (5), Fatigue, Headache and Nausea (4 each), Vaccination site pain (3), Abdominal pain upper, COVID-19, Facial paralysis, Lymphadenopathy, Malaise, Pruritus and Swelling (2 each). Conclusion: No new significant safety information was identified based on a review of these cases compared with the non-paediatric population.

https://www.phmpt.org/wp-content/uploads/2022/04/reissue_5.3.6-postmarketing-experience.pdf

The Pfizer COVID-19 "vaccine" was not approved for use in this age group until October 2021, when the FDA granted EUA authorization for (only) children aged 5 through 11 years. In Table 6, titled "Safety Concerns," the <12 age group appears under the "Missing Information" category.

Table 6 reports 34 cases of use in pediatric individuals. 28 additional cases were excluded because details such as height and weight were "not consistent with pediatric subjects." Pfizer did not supply further details of their pediatric parameters. Country of origin was predominantly UK (29), with an additional three from the U.S. and one each from Germany and Andorra.

https://dailyclout.io/wp-content/uploads/Post-Marketing-Team-Pediatrics-MicroReport.pdf (https://dailyclout.io/wp-content/uploads/Post-Marketing-Team-Pediatrics-MicroReport.pdf)

Please support DailyClout! (https://dailyclout.io/donate/)

This DailyClout article is the writer's opinion.
One of our country's most important freedoms is that of free speech.
Agree with this essay? Disagree? Join the debate by writing to DailyClout HERE. (/submit-a-blog/)

Spread the love

(https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fdailyclout.io%2Freport-54-infants-and-children-under-12-given-the-pfizer-mrna-covid-vaccine-seven-months-before-pediatric-approval-71-suffered-serious-adverse-events%2F)
(http://twitter.com/intent/tweet?text=Report%2054%3A%20Infants%20and%20Children%20Under%2012%20Given%20the%20Pfizer%20mRNA%20COVID%20%E2%80%9CVaccine%E2%80%9D%20Seven%20Months%20BEFORE%20Pediatric%20Approval.%2071%25%20of%20Adverse%20Events%20Suffered%20Serious%20Injury%20or%20Death.%20&url=https%3A%2F%2Fdailyclout.io%2Freport-54-infants-and-children-under-12-given-the-pfizer-mrna-covid-vaccine-seven-months-before-pediatric-approval-71-suffered-serious-adverse-events%2F)
(https://gettr.com/share?text=Report%2054%3A%20Infants%20and%20Children%20Under%2012%20Given%20the%20Pfizer%20mRNA%20COVID%20%E2%80%9CVaccine%E2%80%9D%20Seven%20Months%20BEFORE%20Pediatric%20Approval.%2071%25%20of%20Adverse%20Events%20Suffered%20Serious%20Injury%20or%20Death.%20&url=https%3A%2F%2Fdailyclout.io%2Freport-54-infants-and-children-under-12-given-the-pfizer-mrna-covid-vaccine-seven-months-before-pediatric-approval-71-suffered-serious-adverse-events%2F)
(https://dailyclout.io/report-54-infants-and-children-under-12-given-the-pfizer-mrna-covid-vaccine-seven-months-before-pediatric-approval-71-suffered-serious-adverse-events/)